Wolfgang Miesbach/LinkedIn
May 13, 2026, 15:10
Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Rethinking Bleeding Risk in Anticoagulation.
At the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo delivered a fantastic talk on bleeding risk in patients receiving antithrombotic therapy – from AF and VTE to prosthetic valves, LV thrombus and acute coronary syndromes:
- Antithrombotic therapy is used across many indications, so managing bleeding risk is a daily challenge in routine practice.
- Major bleeding (incl. ICH) remains a major limitation of VKAs and DOACs, and ‘fear‑driven’ underdosing in real life is still common.
- High‑risk patients (age, renal impairment, prior bleeding) live within a narrow therapeutic window, making individualized decisions essential.
- Targeting FXI could help decouple thrombosis from hemostasis, with early data suggesting relevant bleeding reduction while preserving efficacy.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering